Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms

Sho Takatori1, Wenbo Wang1, Akihiro Iguchi1

  • 1Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.

Insights

Alzheimer disease (AD) pathogenesis involves amyloid-beta (Aβ) accumulation. Genetic risk factors, particularly those affecting microglia, are key to understanding AD, highlighting microglia as a potential therapeutic target.

Area of Science:

  • Neuroscience
  • Genetics
  • Immunology

Background:

  • Alzheimer disease (AD) pathogenesis is linked to amyloid-beta (Aβ) accumulation.
  • While gene mutations cause rare AD forms, sporadic AD mechanisms are unclear.
  • Recent genomic studies reveal genetic risk factors for AD.

Purpose of the Study:

  • To review genetic risk factors for Alzheimer disease.
  • To focus on the role of microglia in AD pathogenesis.
  • To explore microglia as a therapeutic target for AD.

Main Methods:

  • Review of current knowledge on AD genetic risk factors.
  • Analysis of genes predominantly expressed in microglia.
  • Discussion of microglial roles in Aβ and tau pathology.

Main Results:

  • Many AD risk genes are expressed in microglia, suggesting shared pathogenic mechanisms.
  • Microglial activation in response to Aβ deposition can be protective or harmful.
  • Microglia are involved in tau pathology and glial cell activation.

Conclusions:

  • Microglia play a central role in Alzheimer disease pathogenesis.
  • Understanding microglial responses to Aβ is crucial for AD research.
  • Microglia represent a promising target for developing new AD therapies.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
708
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
1.3K